{"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"305"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg, administered as IV infusion on Day 1 of each 21-day cycle for up to 35 cycles or until documented PD or participant discontinuation.","id":"BG000","title":"Pembrolizumab"},{"description":"Participants received 1 of 5 possible standard chemotherapy regimens at the investigator's discretion by IV infusion: paclitaxel 200 mg/m\\^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered on Day 1 of each 21-day cycle for 4-6 cycles; pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6, on Day 1 of each 21-day cycle for 4-6 cycles; pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2, on Day 1 of each 21-day cycle for 4-6 cycles; gemcitabine 1250 mg/m\\^2, administered on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, on Day 1 of a 21-day cycle, for 4-6 cycles; gemcitabine 1250 mg/m\\^2, on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m\\^2, on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. Participants with documented disease progression following chemotherapy can switch to receive pembrolizumab for up to 35 cycles (approximately 2 years). Eligible participants who switched to and then stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to 17 cycles (approximately 1 additional year).","id":"BG001","title":"SOC Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.1","value":"63.9"},{"groupId":"BG001","spread":"9.5","value":"64.6"},{"groupId":"BG002","spread":"9.8","value":"64.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"118"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"187"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"283"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"16"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"46"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"251"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"107"}]}],"title":"ECOG = 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"197"}]}],"title":"ECOG = 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"ECOG = 2"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance. ECOG is presented where 0 = Fully active, no performance restrictions; 1 = Strenuous physical activity restricted, fully ambulatory \\& able to carry out light work; and 2 = In bed \\<50% of the time, ambulatory and capable of all self-care, but unable to carry out any work activities.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Status (0, 1 or 2)","unitOfMeasure":"Rating"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"212"}]}],"title":"ADENOCARCINOMA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}],"title":"ADENOSQUAMOUS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}],"title":"LARGE CELL CARCINOMA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"12"}]}],"title":"NON-SQUAMOUS CELL CARCINOMA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"}]}],"title":"POORLY DIFFERENTIATED"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"SARCOMATOID"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"55"}]}],"title":"SQUAMOUS CELL CARCINOMA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA"}],"description":"Participants were categorized according to the histology of their carcinoma","paramType":"NUMBER","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"132"},{"groupId":"BG002","value":"265"}]}],"title":"Non-East Asia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"40"}]}],"title":"East Asia"}],"description":"Count of Participants enrolled in sites in Non-East Asia and East Asia","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region of Enrolling Site","unitOfMeasure":"Participants"}]}